FOXC1 is overexpressed in many cancers such as breast, bladder, colorectal, acute myeloid leukemia (AML), hepatocellular carcinoma, and non-small cell lung cancer10 and is a patented clinical marker for TNBC, particularly for the basal-like phenotype.7 This evidence concerns the gene FOXC1 and cancer.